Barclays share price rebounds on buyback update — UK inflation and jobs data next

Barclays share price rebounds on buyback update — UK inflation and jobs data next

February 16, 2026

London, Feb 16, 2026, 08:27 GMT — Regular session on tap.

  • Barclays shares climbed in early London trading, following news of a new buyback announcement.
  • The bank reported buying 2.745 million shares for cancellation on Feb. 13.
  • Investors eye UK labour-market figures on Feb. 17, then inflation numbers the next day—both set to test bank stocks.

Barclays PLC climbed roughly 2.4% to 465 pence by 0825 GMT, rebounding from last week’s sluggish close. The move came after the bank announced additional share buybacks as part of its latest repurchase plan.

This is notable: the buyback stands out as one of the limited immediate props investors have, while rate bets and persistent UK growth concerns continue to weigh heavily on bank valuations.

This comes just after Friday’s steep slump, with Barclays finishing the session at 454 pence. Traders aren’t sure the selloff is over.

Barclays disclosed in a regulatory filing Monday that it repurchased 2,745,000 ordinary shares on Feb. 13, paying an average of 454.5367 pence apiece. The bank will cancel these shares, trimming its share count with voting rights to 13,812,537,211.

The bank reports snapping up 10,034,750 shares since launching the programme, paying an average 473.3544 pence each. Fewer shares in the market can push up earnings per share, provided profits don’t slip.

Barclays got a lift from the broader market, too. European bank stocks climbed Monday morning, nudging the region’s indexes higher as investors eased into earnings season and kept an eye out for new economic numbers.

For the UK, attention now shifts to a trio of domestic data drops: labour-market stats hit on Tuesday, with January inflation figures landing Wednesday and retail sales to follow on Friday. Each of these releases often jolts rate-cut bets—and bank stocks tend to move in step. Gov Gov

The math is simple for banks such as Barclays. Much of their income hinges on the spread between lending rates and what they give to depositors. Fast rate cuts threaten to compress that margin. But if inflation proves stubborn, rates might stay elevated—good for the spread, but it stirs up anxiety over the pace of economic growth.

Bank of England policy maker Catherine Mann, in a Sunday newspaper interview, cautioned against putting too much weight on the jump in youth unemployment. Still, she did tie the trend to wage policy and the broader labour market—major factors in the BoE’s ongoing inflation discussions. “Very unfortunate, but it is true. It is a fact,” Mann said. Reuters

Still, the buyback wouldn’t offer much protection if fresh data this week nudges investors into pricing in sharper rate cuts. Flip side: should inflation run hotter than expected, renewed concerns over consumer strain and potential loan losses could easily resurface.

Tuesday brings the labour-market report (Feb. 17); inflation numbers land Wednesday (Feb. 18), and Friday wraps up with retail sales data (Feb. 20). Barclays’ ongoing buyback programme could also yield more disclosures as the week unfolds.

Artur Ślesik

Artur Ślesik is a technology and financial markets journalist at Bez-kabli.pl, covering artificial intelligence, semiconductors, technology stocks and emerging innovations. A graduate of Warsaw University of Technology, he combines a technical background with market analysis to explain how new technologies are shaping industries, businesses and investment trends worldwide.

Stock Market Today

  • Sonic Healthcare (ASX:SHL) Slips Early in 2025, Still Draws Interest on Revenue and Growth
    July 17, 2026, 6:52 PM EDT. Sonic Healthcare Ltd (ASX:SHL) shares dipped 2.5% early in 2025. The stock still gets attention for its footprint in pathology, diagnostics, and medical services worldwide. Healthcare names like SHL see steady business from 'sticky' revenue as patient spending tends to hold up in tough markets. The ASX200 Healthcare Index has lagged behind the wider market but stays steady over time. Outlook for the sector stays solid, with US healthcare spending forecast to climb 7% a year out to 2027. Some areas-healthcare IT and SaaS-are tipped to grow revenue by more than 15%. Ethical money keeps flowing into the space. SHL, with rising sales, trades at 1.21x price-to-sales, below the five-year average of 1.94x. Valuation's not the only call for anyone weighing the shares.